Trial · NCT00309946
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
NCT00309946, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2013-09-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery. Trials, record NCT00309946. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00309946
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
- NCT number
- NCT00309946
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 51 participants, actual
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
- Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
- Interventions
- cediranib maleate
- First posted
- 2006-04-03
- Last updated
- 2014-07-31
- Results first posted
- 2013-09-10
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate, Complete (CR) or Partial (PR) Response | Every 8 weeks | Evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. To be assigned a status of PR or CR, changes in tumor measurements must be confirmed by repeat assessments that should be performed no less than 4 weeks after the criteria for response are first met. |
| Secondary | Changes in Laboratory Correlates | Baseline, days 15 and 29 of course 1, and then every 28 days | Examined using paired t-test or Wilcoxon signed-ranks test. |
| Secondary | Pharmacogenomics by Correlating Genetic Polymorphisms With Drug Activity and Toxicity | Week 1 of course 1 | Focus on variants of genes in the pathway targeted by cediranib maleate, including kdr/flk-1 (the specific target of cediranib maleate) and the genes that encode Vascular endothelial growth factor A (VEGF-A) or HIF1α. If additional information relevant to other genes of interest in the pathway becomes available the samples will be utilized for such analysis as well. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Objective Response Rate, Complete (CR) or Partial (PR) Response | Every 8 weeks | percentage of participants | NUMBER | |
| SECONDARY | Changes in Laboratory Correlates | Baseline, days 15 and 29 of course 1, and then every 28 days | This outcome was not measured/assessed for any of the study subjects. | ||
| SECONDARY | Pharmacogenomics by Correlating Genetic Polymorphisms With Drug Activity and Toxicity | Week 1 of course 1 | This outcome was not measured/assessed for any of the study subjects. |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate, Complete (CR) or Partial (PR) Response | Treatment (Enzyme Inhibitor Therapy) | 5 | percentage of participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment (Enzyme Inhibitor Therapy) | 51 | |
| Overall Study | COMPLETED | Treatment (Enzyme Inhibitor Therapy) | 50 | |
| Overall Study | NOT COMPLETED | Treatment (Enzyme Inhibitor Therapy) | 1 |
Source ClinicalTrials.gov
Adverse events108
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | General disorders | Treatment (Enzyme Inhibitor Therapy) | 8 | 51 | |
| other | Alanine aminotransferase (ALT) increased | Metabolism and nutrition disorders | Treatment (Enzyme Inhibitor Therapy) | 11 | 51 | |
| other | Alkaline phosphatase (ALP) increased | Metabolism and nutrition disorders | Treatment (Enzyme Inhibitor Therapy) | 9 | 51 | |
| other | Allergic rhinitis | Immune system disorders | Treatment (Enzyme Inhibitor Therapy) | 4 | 51 | |
| other | Anemia | Blood and lymphatic system disorders | Treatment (Enzyme Inhibitor Therapy) | 23 | 51 | |
| other | Anorexia | Gastrointestinal disorders | Treatment (Enzyme Inhibitor Therapy) | 28 | 51 | |
| other | Anxiety | Nervous system disorders | Treatment (Enzyme Inhibitor Therapy) | 5 | 51 | |
| other | Arthralgia | General disorders | Treatment (Enzyme Inhibitor Therapy) | 4 | 51 | |
| other | Aspartate aminotransferase (AST) increased | Metabolism and nutrition disorders | Treatment (Enzyme Inhibitor Therapy) | 10 | 51 | |
| other | Back pain | General disorders | Treatment (Enzyme Inhibitor Therapy) | 10 | 51 |
1 to 10 of 108Source ClinicalTrials.gov
See all 108 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment (Enzyme Inhibitor Therapy) | ||
| Total, other adverse events | Treatment (Enzyme Inhibitor Therapy) | 49 | 51 |
| Total, serious adverse events | Treatment (Enzyme Inhibitor Therapy) | 31 | 51 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22831987 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00309946
GET https://conductscience.org/api/trials/v1/NCT00309946/events?page=2